Vera Therapeutics (VERA) Total Current Liabilities (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Total Current Liabilities data on file, last reported at $45.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 106.22% year-over-year to $45.1 million; the trailing twelve-month figure through Mar 2026 stood at $45.1 million (up 106.22% YoY), and the FY2025 full-year result was $53.5 million, up 110.69% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $45.1 million, down from $53.5 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $53.5 million in Q4 2025 and bottomed at $14.5 million in Q1 2024.
• The 5-year median for Total Current Liabilities is $24.6 million (2023), against an average of $26.9 million.
• The widest annual swing landed in 2022, when Total Current Liabilities surged 432.08%; it then sank 38.19% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $25.6 million in 2022, then fell by 12.88% to $22.3 million in 2023, then advanced by 13.76% to $25.4 million in 2024, then soared by 110.69% to $53.5 million in 2025, then retreated by 15.54% to $45.1 million in 2026.
• The last three Total Current Liabilities figures came in at $45.1 million (Q1 2026), $53.5 million (Q4 2025), and $41.9 million (Q3 2025), per Business Quant data.

Peer Comparison